key: cord-0939308-pqq9jv3v authors: Larenas-Linnemann, Désirée; Rodríguez-Pérez, Noel; Ortega-Martell, Jose Antonio; Vijil, Virginia Blandon; Luna-Pech, Jorge A. title: COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations date: 2020-06-10 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2020.06.009 sha: 394ea6e5206bfbb481b2abc0e14f85e15ab7e1c3 doc_id: 939308 cord_uid: pqq9jv3v nan COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations 1. Funding Source: none. The following suggestions should always be weighted in the light of the local situation in the 63 clinic or hospital where AIT is administered, as the risk of SARS-CoV-2 transmission varies widely 64 among places, as it shall vary in time over the months to come. 65 To space AIT administrations or not; to start AIT or not 66 Bearing all this in mind, we could conclude there is a possible advantage AIT might bring to the 67 patient during the pandemic. Thus, we would like to argue that the prime focus should be on 68 continuing AIT under the binomial AIT efficacy+safety, interpreting safety as the maximum 69 effort to reduce the risk of transmission. However, when it is suggested to space AIT 70 administrations as much as safety (=no adverse events secondary to AIT) allows, we are giving 71 in on efficacy, as this is linked to the monthly dose. (13) In the same line we would like to argue 72 in favor of starting AIT, preferably SLIT, or, in clinics where social distancing can be practiced, 73 SCIT can be an option. 74 Maximum reduction of transmission risk 75 The workgroups gave several suggestions. We would like to add some that were not present in 76 all documents. 77 • Strict hand sanitizing as soon as patients come into the office 78 • Face-masks obligatory 79 • Separate AIT administration time from patient-consulting time. 80 • Start early, when there is little movement on the streets and in the clinics 81 • Pre-screening before coming to the clinic: suspicious symptoms over the past 2 weeks. 82 If positive: online physician interview. 83 • Pre-shot screening: peak-flow yes, but at home. 84 30 minute waiting after-shot in the car 85 Consider allowable, for low-risk, controlled patients. 86 87 It shall probably still take several months at least until SARS-CoV-2 is over, and it might very 88 well be many shall finally get infected. It is important to enhance best possible our own and 89 our patients' innate immunity to have it prepared for giving the first strike and not let the virus 90 advance. AIT might play a role in this doing. 91 Administration of subcutaneous allergen immunotherapy during the COVID-19 outbreak: A Work Group Report of the AAAAI Immunotherapy, Allergen Standardization and Allergy Diagnostics (IASAD) Committee Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement Preparing your office for the COVID-19 Pandemic Imbalanced host response to SARS-CoV-2 drives development of COVID-19 Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Cytokine release syndrome in severe COVID-19 Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers Mechanisms of Subcutaneous and Sublingual Aeroallergen Immunotherapy: What Is New? Sequential conditioningstimulation reveals distinct gene-and stimulus-specific effects of Type I and II IFN on human macrophage functions Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite State-ofthe-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI) European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy' We would like to thank the members of the Mexican Allergen Immunotherapy workgoup Immune changes secondary to AIT and their interaction with COVID-19, at some points binominal. AIT reestablishes the function of dendritic cells (DCs), enhancing their production of interferon (IFN), see below. Also, instead of producing type 2 cytokines, DCs start releasing type 1 cytokines, thus favoring the development of T helper 1 cells and regulatory T cells. This favors the patient when facing a viral infection as Th1 cells drive the activation of cytotoxic T cells, important for the adaptive elimination of the virus. In COVID-19, regulatory T cells and cytokines (IL-10 and TGF-β) could reduce the cytokine storm, though in the beginning of an infection their inhibitory action might not be wishful. The first line defense against viruses is IFN, of note type I (α and β) and type III (λ). AIT induces IFN production, mainly IFN-γ, but IFN-α is also produced by DCs after AIT. This is beneficial at first contact with the virus, but as IFN-γ stimulates macrophages this could not be advantageous in the critically ill.